12:00 AM
May 21, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Blinatumomab: Phase II data

Data from 36 evaluable adults with B-precursor ALL who relapsed following standard front-line chemotherapy or allogeneic stem cell transplant in a single-arm, dose-ranging, international Phase II trial showed that 26 (72%) patients achieved a CR or CR with partial recovery of blood counts following treatment with once-daily 5-30 µg/m 2 blinatumomab. Additionally, 34 patients achieved a molecular response, defined as no evidence of...

Read the full 293 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >